<DOC>
	<DOCNO>NCT01813643</DOCNO>
	<brief_summary>Methamphetamine-associated psychosis ( MAP ) consider pharmacological environmental pathogen model schizophrenia ( SCZ ) due part similarity clinical presentation ( i.e . paranoia , hallucination , disorganize speech , negative symptom ) , response treatment ( e.g.neuroleptics ) , pathologic mechanism ( e.g . central dopaminergic neurotransmission ) condition . Both risperidone aripiprazole second generation antipsychoticsï¼Œbut different pharmacological effect antipsychotic treatment.This study design examine acute efficacy , safety , tolerability risperidone aripiprazole patient MAP .</brief_summary>
	<brief_title>A Comparison Risperidone Aripiprazole Treatment Patirnts With Methamphetamine-Associated Psychosis</brief_title>
	<detailed_description>Methods : A Multiple-Center , Randomized , Double-Blind .</detailed_description>
	<mesh_term>Methamphetamine</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<mesh_term>Aripiprazole</mesh_term>
	<criteria>1 . Patients , Diagnostic Statistical Manual Mental Disorders 4thed . ( DSMIV ) criterion MethamphetamineAssociated Psychosis . 2 . Must sign Information consent form . 3 . Required provide detailed address phone number 1 . Serious organic disease . 2 . Suicide ideation hurt others . 3 . Taking antipsychotic within two week . 4. drug allergy Risperidone Aripiprazole . 5. pregnancy breastfeed woman .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Methamphetamine-Associated Psychosis</keyword>
	<keyword>Aripiprazole</keyword>
	<keyword>Risperidone</keyword>
</DOC>